Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Comparative Effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia With Vancomycin MIC >1 mg/L: A Multicenter Evaluation.

Moise PA, Culshaw DL, Wong-Beringer A, Bensman J, Lamp KC, Smith WJ, Bauer K, Goff DA, Adamson R, Leuthner K, Virata MD, McKinnell JA, Chaudhry SB, Eskandarian R, Lodise T, Reyes K, Zervos MJ.

Clin Ther. 2016 Jan 1;38(1):16-30. doi: 10.1016/j.clinthera.2015.09.017. Epub 2015 Nov 14.

PMID:
26585355
2.

Clinical Outcomes of Daptomycin for Vancomycin-resistant Enterococcus Bacteremia.

Moise PA, Sakoulas G, McKinnell JA, Lamp KC, DePestel DD, Yoon MJ, Reyes K, Zervos MJ.

Clin Ther. 2015 Jul 1;37(7):1443-1453.e2. doi: 10.1016/j.clinthera.2015.04.008. Epub 2015 May 15.

PMID:
25982687
3.

Staphylococcus aureus bacteraemia management: where do we stand and where are we going?

Moise PA, Sakoulas G.

Evid Based Med. 2015 Aug;20(4):126. doi: 10.1136/ebmed-2014-110122. Epub 2015 Apr 20. No abstract available.

PMID:
25895528
4.

Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline.

Sakoulas G, Moise PA, Casapao AM, Nonejuie P, Olson J, Okumura CY, Rybak MJ, Kullar R, Dhand A, Rose WE, Goff DA, Bressler AM, Lee Y, Pogliano J, Johns S, Kaatz GW, Ebright JR, Nizet V.

Clin Ther. 2014 Oct 1;36(10):1317-33. doi: 10.1016/j.clinthera.2014.05.061. Epub 2014 Jul 10.

PMID:
25017183
5.

Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant β-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment.

Moise PA, Amodio-Groton M, Rashid M, Lamp KC, Hoffman-Roberts HL, Sakoulas G, Yoon MJ, Schweitzer S, Rastogi A.

Antimicrob Agents Chemother. 2013 Mar;57(3):1192-200. doi: 10.1128/AAC.02192-12. Epub 2012 Dec 17.

6.
7.

Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium.

Sakoulas G, Bayer AS, Pogliano J, Tsuji BT, Yang SJ, Mishra NN, Nizet V, Yeaman MR, Moise PA.

Antimicrob Agents Chemother. 2012 Feb;56(2):838-44. doi: 10.1128/AAC.05551-11. Epub 2011 Nov 28.

8.

Retrospective observational study comparing vancomycin versus daptomycin as initial therapy for Staphylococcus aureus infections.

Jobson S, Moise PA, Eskandarian R.

Clin Ther. 2011 Oct;33(10):1391-9. doi: 10.1016/j.clinthera.2011.09.007. Epub 2011 Oct 19.

PMID:
22015328
9.
10.

Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions.

Moise PA, North D, Steenbergen JN, Sakoulas G.

Lancet Infect Dis. 2009 Oct;9(10):617-24. doi: 10.1016/S1473-3099(09)70200-2. Review.

PMID:
19778764
11.

Reduced biofilm production associated with increasing linezolid MICs among linezolid-resistant staphylococci.

Dandache P, Moise PA, Orsini J, Montecalvo M, Sakoulas G.

J Antimicrob Chemother. 2009 Nov;64(5):1114-5. doi: 10.1093/jac/dkp324. Epub 2009 Sep 4. No abstract available.

PMID:
19734169
12.

Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy.

Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC.

Ann Pharmacother. 2009 Jul;43(7):1211-9. doi: 10.1345/aph.1M085. Epub 2009 Jul 7.

PMID:
19584384
13.

Accessory gene regulator dysfunction: an advantage for Staphylococcus aureus in health-care settings?

Sakoulas G, Moise PA, Rybak MJ.

J Infect Dis. 2009 May 15;199(10):1558-9. doi: 10.1086/598607. No abstract available.

PMID:
19392634
14.

Genotypic and phenotypic relationships among methicillin-resistant Staphylococcus aureus from three multicentre bacteraemia studies.

Moise PA, Smyth DS, Robinson DA, El-Fawal N, McCalla C, Sakoulas G.

J Antimicrob Chemother. 2009 May;63(5):873-6. doi: 10.1093/jac/dkp047. Epub 2009 Mar 3.

15.

Vancomycin ototoxicity: a reevaluation in an era of increasing doses.

Forouzesh A, Moise PA, Sakoulas G.

Antimicrob Agents Chemother. 2009 Feb;53(2):483-6. doi: 10.1128/AAC.01088-08. Epub 2008 Nov 10.

16.

Microbiological and genotypic analysis of methicillin-resistant Staphylococcus aureus bacteremia.

McCalla C, Smyth DS, Robinson DA, Steenbergen J, Luperchio SA, Moise PA, Fowler VG Jr, Sakoulas G.

Antimicrob Agents Chemother. 2008 Sep;52(9):3441-3. doi: 10.1128/AAC.00357-08. Epub 2008 Jul 7.

17.

Relationship of linezolid minimum inhibitory concentration and time to bacterial eradication in treatment for methicillin-resistant Staphylococcus aureus infection.

Moise PA, Castro RS, Sul C, Forrest A, Sakoulas G.

Ann Pharmacother. 2008 Apr;42(4):592-3. doi: 10.1345/aph.1K613. Epub 2008 Mar 18. No abstract available.

PMID:
18349303
18.

Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia.

Moise PA, Smyth DS, El-Fawal N, Robinson DA, Holden PN, Forrest A, Sakoulas G.

J Antimicrob Chemother. 2008 Jan;61(1):85-90. Epub 2007 Nov 27.

PMID:
18042628
19.

Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia.

Moise PA, Sakoulas G, Forrest A, Schentag JJ.

Antimicrob Agents Chemother. 2007 Jul;51(7):2582-6. Epub 2007 Apr 23.

20.

Pharmacokinetic and pharmacodynamic modelling of antibiotic therapy.

Moise PA, Schentag JJ.

Curr Opin Infect Dis. 1998 Dec;11(6):673-80.

PMID:
17035742
21.

Clinical experience with linezolid in conjunction with wound coverage techniques for skin and soft-tissue infections and postoperative osteomyelitis.

Broder KW, Moise PA, Schultz RO, Forrest A, Schentag JJ.

Ann Plast Surg. 2004 Apr;52(4):385-90.

PMID:
15084884
22.

Pharmacokinetics and metabolism of moxifloxacin.

Moise PA, Birmingham MC, Schentag JJ.

Drugs Today (Barc). 2000 Apr;36(4):229-44.

PMID:
12879119
23.
24.

Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections.

Moise PA, Schentag JJ.

Int J Antimicrob Agents. 2000 Nov;16 Suppl 1:S31-4. Review.

PMID:
11137406
25.

Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus.

Moise PA, Forrest A, Bhavnani SM, Birmingham MC, Schentag JJ.

Am J Health Syst Pharm. 2000 Oct 15;57 Suppl 2:S4-9. Erratum in: Am J Health Syst Pharm 2001 Jan 1;58(1):78.

PMID:
11057360

Supplemental Content

Loading ...
Support Center